SELLAS Life Sciences Group Business Summary

SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company that operates primarily through the development and potential commercialization of novel cancer immunotherapies and targeted therapies. The company’s revenue model is currently centered on strategic collaborations and licensing agreements, generating capital through milestone payments and research funding rather than direct product sales. Its primary business segments are focused on its two lead assets: Galinpepimut-S (GPS), a WT1-targeting peptide immunotherapy licensed from Memorial Sloan Kettering Cancer Center, and SLS009 (tambiciclib), a highly selective CDK9 inhibitor. SELLAS competes directly with oncology-focused firms such as Agenus, Marker Therapeutics, and Adaptimmune Therapeutics. Within this landscape, SELLAS distinguishes itself by targeting the Wilms Tumor 1 (WT1) antigen—ranked as a top priority by the National Cancer Institute—and advancing pivotal Phase 3 trials for Acute Myeloid Leukemia (AML). The company was founded by Dr. Angelos M. Stergiou, who serves as President and CEO; his pedigree includes co-founding Genesis Life Sciences and holding senior roles at PAION AG and Anavex Life Sciences. The executive team is further anchored by John T. Burns, CPA, who serves as Senior Vice President and CFO with a background in public accounting at Moss Adams and corporate finance at Pixelworks. Clinical and technical operations are led by Dr. Dragan Cicic, Senior Vice President and Chief Development Officer, who brings over 20 years of biopharmaceutical experience from Klus Pharma and other oncology-focused entities. The board of directors features notable industry veterans including Chairman John Varian, former CEO of XOMA, and Dr. David A. Scheinberg of Memorial Sloan Kettering. SELLAS maintains a strong institutional investor base, with significant holdings from firms such as Vanguard Group, Charles Schwab Investment Management, and Goldman Sachs.